A Phase III Trial to Assess the Efficacy and Safety of Recombinant Human Prourokinase in the Treatment of Acute Ischaemic Stroke in 4.5-6 Hours After Stroke Onset
Phase of Trial: Phase III
Latest Information Update: 18 Jan 2019
Price : $35 *
At a glance
- Drugs Saruplase (Primary) ; Aspirin
- Indications Stroke
- Focus Registrational; Therapeutic Use
- Acronyms PROUD
- Sponsors Tasly Pharmaceuticals, Inc.
- 09 Jan 2019 Status changed from not yet recruiting to recruiting.
- 12 Jul 2018 New trial record